pCPA Activity Overview
| Status | Total Negotiations | Summary |
|---|---|---|
| Active Negotiations | 35 | Non-oncology: 21 Oncology: 14 |
| Under Consideration for Negotiation | 27 | Non-oncology: 17 Oncology: 10 |
| Completed Negotiations | 681 | With Letter of Intent: 584 Without agreement: 97 |
| Negotiations That Were Not Pursued | 103 |
pCPA Activity in the last four weeks
Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.
Engagement Letters Issued in the last four weeks
| Brand Name | Manufacturer | Indication | Engagement Date |
|---|---|---|---|
| To be confirmed | Sandoz Canada Inc. | Multiple Indications | |
| Jubbonti | Sandoz Canada Inc. | Multiple indications | |
| Wyost | Sandoz Canada Inc. | Multiple Indications | |
| Epkinly (pTAP negotiation) | AbbVie Corporation | For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS), DLBCL transformed from indolent lymphoma, high grade B-cell lymphoma (HGBCL), primary mediastinal B-cell lymphoma (PMBCL) or | |
| Cabometyx | Ipsen Biopharmaceuticals | Cabometyx in combination with nivolumab, is indicated for the first-line treatment of adult patients with advanced (not amenable to curative surgery or radiation therapy) or metastatic RCC | |
| Columvi | Hoffmann-La Roche Limited | Glofitamab is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from follicular lymphoma (trFL), or primary mediastinal B-cell lymphoma (PMBCL), who have |